Clinical Trials Directory

Trials / Terminated

TerminatedNCT02244944

Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

The Effect of Ezetimibe-Ursodiol Combination Therapy on Biomarkers of Liver Function and Sterol Balance in Subjects With NAFLD

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
2 (actual)
Sponsor
Gregory Graf, PhD · Academic / Other
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The purpose of this research is to gather information on the combination Zetia® (Ezetimibe) and Urso Forte® with respect to sterol balance and their effects on biomarkers of liver function in subjects with nonalcoholic fatty liver disease (NAFLD).

Detailed description

The study will be conducted as a prospective open label trial with pre- and post-treatment measures for all dependent variables. This trial will enroll subjects with a clinical diagnosis of nonalcoholic fatty liver disease (NAFLD) by magnetic resonance imaging (MRI), computed tomography (CT) or ultrasound, including those diagnosed with nonalcoholic steatohepatitis (NASH). Subjects will be consented, blood collected and a MRI conducted on the first visit. Patients will be advised on the proper use of the study drug and given the first three month's supply of the study drug to take home with them. For the remaining three months, study drug will be delivered by US mail along with return packaging for the prior three month's study medication in order to monitor compliance. Patients will be called routinely to encourage compliance, retention, and monitor side effects or adverse events. After six months of study drug administration, subjects will return for a follow-up visit. Blood will be drawn, an MRI will be obtained and a post-study questionnaire will be administered. Duration of Patient Enrollment: 6 months Duration of Study: 18 months

Conditions

Interventions

TypeNameDescription
DRUGEZ-Urso combination therapyUrsodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day

Timeline

Start date
2014-09-01
Primary completion
2015-09-01
Completion
2015-09-01
First posted
2014-09-19
Last updated
2018-02-07
Results posted
2018-02-07

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT02244944. Inclusion in this directory is not an endorsement.